

## (19) World Intellectual Property Organization International Bureau





(43) International Publication Date 23 October 2003 (23.10.2003)

**PCT** 

## (10) International Publication Number WO 2003/086314 A3

(51) International Patent Classification<sup>7</sup>: A61K 31/439, C07D 221/22, A61P 35/00

(21) International Application Number:

PCT/US2003/012456

(22) International Filing Date: 8 April 2003 (08.04.2003)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/372,358 12 April 2002 (12.04.2002)

(71) Applicant (for all designated States except US): MERCK & CO., INC. [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(72) Inventor; and

(75) Inventor/Applicant (for US only): KIM, Annette [US/US]; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US).

(74) Common Representative: MERCK & CO., INC.; 126 East Lincoln Avenue, Rahway, NJ 07065-0907 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## Published:

with international search report

(88) Date of publication of the international search report: 8 April 2004

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: TYROSINE KINASE INHIBITORS

(57) Abstract: The present invention relates to compounds that are capable of inhibiting, modulating and/or regulating signal transduction of both receptor-type and non-receptor type tyrosine kinases. The compounds of the instant invention possess a core structure that comprises a benzazocine moiety. The present invention is also related to the pharmaceutically acceptable salts, hydrates and stereoisomers of these compounds.



	·	
International	plication	No

PCT/US03/12456

US CL	IPC(7) : A61K 31/439; C07D 221/22; A61P 35/00 US CL : 514/295; 546/93			
	International Patent Classification (IPC) or to both i	national classification and IPC		
	DS SEARCHED			
Minimum documentation searched (classification system followed by classification symbols) U.S.: 514/295; 546/93				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) CAS ONLINE				
C. DOCUMENTS CONSIDERED TO BE RELEVANT				
Category *	Citation of document, with indication, where a		Relevant to claim No.	
X	US 4,332,810 (BELANGER et al.) 01 June 1982 (01.06.1982), columns 11-13, Examples 1, 2, 6		1, 2, 6	
x	1-4. BELANGER et al. Preparation and stereochemistry of 8- and 9- hydroxy-2,5-ethano-3- benzazocines. Can. J. Chem. 1983, Vol. 61, pages 2177-2182, especially page 2177, compounds 6, 8, and page 2178, compounds 11, 15.			
x	IDDON et al. Synthesis and reactions of 2,3,5,6-tetrahydro-2,5-ethano-3-benzazocin-4(1H)-one and a thieno-extended analogue: X-ray structure of 3-methyl-2,3,5,6-tetrahydro-2,5-ethano[1]benzothieno[3,2-d]azocin-4(1H)-one. J. Chem. Soc. Perkin Trans. 1. 1990, Vol. 4, pages 1083-1090, especially page 1085, compounds 24, 25.			
A	WORKMAN et al. Tyrosine kinase inhibitors. Sem pages 369-381.	inars in Cancer Biology. 1992, Vol. 3,	1-21	
Further	documents are listed in the continuation of Box C.	See patent family annex.		
• S	pecial categories of cited documents:	"T" later document published after the int		
	priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention			
•	licular relevance plication or patent published on or after the international filing	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		
	which may throw doubts on priority claim(s) or which is cited sh the publication date of another citation or other special reason ied)	"Y"  document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		
	referring to an oral disclosure, use, exhibition or other means	"&" document member of the same patent	family	
priority o	published prior to the international filing date but later than the	Day of the second secon		
	ctual completion of the international search (09.07.2003)	Date of mailing of the international search report  0 4 DEC 2003  Authorized officer  Comparison Co		
	ailing address of the ISA/US	Authorized officer QQ	to pos	
	il Stop PCT, Atm: ISA/US	Everyn Huang		
P.O	nmissioner for Patents D. Box 1450			
	xandria, Virginia 22313-1450	Telephone No. 703-308-1235		

Form PCT/ISA/210 (second sheet) (July 1998)